Soligenix(SNGX)

Focus: Soligenix is a public biotech company focused on lipoprotein delivery and small molecule therapeutics across oncology, gastroenterology, and immunology. The company is in early-stage clinical development with minimal commercial revenue.

Oncology Gastroenterology Immunology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Soligenix

AI assessmentNot Hiring

No open roles listed right now. Follow Soligenix to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$119K

Pipeline & Clinical Trials

SGX201

Enteritis

PHASE_1_2

Clinical Trials (1)

NCT01073384A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer

Phase 1/2

Help build intelligence for Soligenix

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to proprietary lipoprotein delivery platform with applications across multiple therapeutic areas
Portfolio spans Phase 3 programs (Hypericin for CTCL, SGX301, SGX942) offering near-term clinical catalysts
Focused pipeline of 12 active programs with 4 in Phase 3, providing meaningful drug development experience

Watch Out For

Severe cash burn: FY2025 revenue of $119K against $5M R&D spend and $8.3M net loss signals substantial funding pressure
No active hiring (0 open positions) and pre-commercial stage mean limited organizational expansion and career progression opportunities
Minimal publications (5) and near-zero commercial revenue suggest limited resources for infrastructure and mentorship

Generated by Claude from Soligenix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

orBec

Chronic Gastrointestinal Graft vs Host Disease

PHASE_2

Clinical Trials (1)

NCT01925950Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Phase 2

Hypericin

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

PHASE_2

Clinical Trials (1)

NCT06149247HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Phase 2

Hypericin

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

PHASE_2

Clinical Trials (1)

NCT05380635PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Phase 2

Hypericin

Cutaneous T Cell Lymphoma

PHASE_2

Clinical Trials (1)

NCT05872854Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Phase 2

Dusquetide

Behçet Disease

PHASE_2

Clinical Trials (1)

NCT06386744Dusquetide for the Treatment of Behcet's Disease

Phase 2

Hypericin

Psoriasis

PHASE_2

Clinical Trials (1)

NCT05442190Topical SGX302 for Mild-to-Moderate Psoriasis

Phase 2

SGX942

Oral Mucositis

PHASE_2

Clinical Trials (1)

NCT02013050A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

Phase 2

SGX301

Cutaneous T-Cell Lymphoma

PHASE_3

Clinical Trials (1)

NCT02448381FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Phase 3

Hypericin

CTCL/ Mycosis Fungoides

PHASE_3

Clinical Trials (1)

NCT06470451Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Phase 3

oral beclomethasone 17,21-dipropionate

Acute Gastrointestinal Graft vs Host Disease

PHASE_3

Clinical Trials (1)

NCT00926575Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)

Phase 3

SGX942

Squamous Cell Carcinoma of the Oral Cavity and Oropharynx

PHASE_3

Clinical Trials (1)

NCT03237325DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 12 clinical trials

Top TAs: Oncology, Gastroenterology, Immunology

Publications: 26 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

6 pipeline

Gastroenterology

2 pipeline

Immunology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$119K86%

R&D Spend

$5M(4376%)58%

Net Income

-$8M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor(®) (Mechlorethamine) in the Treatment of CTCL.

Oncology and therapy

2026

PMID:41920467

Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome.

Rheumatology (Oxford, England)

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Soligenix(SNGX)

About Soligenix

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Soligenix(4)

Open Jobs (0)

Financials (FY2025)

Research Publications(10)